Korro Bio Inc (KRRO)

Feb 23, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Buy” from Analysts - Defense World

Feb 23, 2025

Feb 20, 2025

KRRO stock touches 52-week low at $28.71 amid market challenges - Investing.com Nigeria

Feb 20, 2025

Feb 13, 2025

Korro Bio CFO takes medical leave, interim officers appointed - MSN

Feb 13, 2025

Feb 11, 2025

Korro Bio CFO takes medical leave, interim officers appointed By Investing.com - Investing.com Nigeria

Feb 11, 2025

Feb 11, 2025

Korro Bio Appoints Interim CFO Amid Medical Leave - TipRanks

Feb 11, 2025

Feb 11, 2025

Korro Bio, Inc. Appoints Oliver Dolan as Interim Principal Accounting Officer -February 11, 2025 at 04:05 pm EST - Marketscreener.com

Feb 11, 2025

Feb 11, 2025

KRRO stock touches 52-week low at $29.8 amid yearly slump - Investing.com

Feb 11, 2025

Feb 05, 2025

AllianceBernstein L.P.'s Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com

Feb 05, 2025

Feb 01, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Feb 01, 2025

Jan 30, 2025

JPMorgan Chase & Co. Boosts Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat

Jan 30, 2025

Jan 30, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Shares Bought by JPMorgan Chase & Co. - Defense World

Jan 30, 2025

Jan 29, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Buy” from Analysts - Defense World

Jan 29, 2025

Jan 20, 2025

Korro Bio (NASDAQ:KRRO) Doses First Participants in REWRITE Phase 1/2a Clinical Study – Pipeline Update ProvidedOn January 13, 2025, Korro Bio, Inc. issued a press release stating that it had initiated dosing the first participants in its REWRITE Pha - Defense World

Jan 20, 2025

Jan 18, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Update - MarketBeat

Jan 18, 2025

Jan 13, 2025

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com

Jan 13, 2025

Jan 13, 2025

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update - The Manila Times

Jan 13, 2025

Jan 13, 2025

Korro Bio Launches First Clinical Trial for AATD Treatment KRRO-110, Marks Clinical Stage Milestone - StockTitan

Jan 13, 2025

Jan 13, 2025

Korro Bio (NASDAQ:KRRO) Research Coverage Started at Oppenheimer - Defense World

Jan 13, 2025

Jan 10, 2025

Korro Bio (NASDAQ:KRRO) Now Covered by Analysts at Oppenheimer - MarketBeat

Jan 10, 2025

Jan 07, 2025

Korro Bio CEO to Present RNA Editing Breakthroughs at JP Morgan Healthcare Conference - StockTitan

Jan 07, 2025

Jan 06, 2025

Geode Capital Management LLC Sells 2,161 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World

Jan 06, 2025

Jan 04, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Jan 04, 2025

Dec 31, 2024

Korro Bio, Inc. (NASDAQ:KRRO) Stock Position Increased by State Street Corp - MarketBeat

Dec 31, 2024

Dec 31, 2024

State Street Corp Acquires 18,877 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World

Dec 31, 2024

Dec 23, 2024

Korro Bio: Still Too Long To Go… Just Keep Watching For Now (Rating Upgrade) (NASDAQ:KRRO) - Seeking Alpha

Dec 23, 2024

Dec 21, 2024

Wellington Management Group LLP Invests $436,000 in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat

Dec 21, 2024

Dec 20, 2024

Frequency Therapeutics : The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Frequency Therapeutics, Inc. (FREQ) Investors - Marketscreener.com

Dec 20, 2024

Dec 18, 2024

BNP Paribas Financial Markets Purchases 4,470 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World

Dec 18, 2024

Dec 16, 2024

Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical catalyst - Investing.com Nigeria

Dec 16, 2024

Dec 11, 2024

Fmr LLC Has $19.37 Million Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat

Dec 11, 2024

Dec 10, 2024

Why Korro Bio (KRRO) Should Be on Your Investment Radar - Nasdaq

Dec 10, 2024

Dec 10, 2024

Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Dec 10, 2024

Dec 09, 2024

100-employee biotech opens new Kendall Square HQ - The Business Journals

Dec 09, 2024

Dec 05, 2024

Verition Fund Management LLC Has $3.12 Million Stake in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat

Dec 05, 2024

Dec 04, 2024

Korro Bio to Begin RNA-Editing Trial in Alpha-1 Antitrypsin Deficiency - CRISPR Medicine News

Dec 04, 2024

Dec 04, 2024

Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Down 6.5% in November - Defense World

Dec 04, 2024

Dec 01, 2024

Quest Partners LLC Has $59,000 Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World

Dec 01, 2024

Nov 30, 2024

Eventide Asset Management LLC Sells 137,989 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat

Nov 30, 2024

Nov 28, 2024

We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully - Simply Wall St

Nov 28, 2024

Nov 26, 2024

Korro Bio, Inc Receives Approval from the Australian Bellberry Human Research Ethics Committee and Clearance from the Australian Therapeutic Goods Administration to Initiate A Phase 1/2A Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com

Nov 26, 2024

Nov 26, 2024

Korro Bio's SWOT analysis: RNA editing stock poised for growth amid AATD treatment race - Investing.com

Nov 26, 2024

Nov 24, 2024

HC Wainwright Reaffirms Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World

Nov 24, 2024

Nov 23, 2024

Korro Bio (NASDAQ:KRRO) Trading 9.3% HigherHere's What Happened - MarketBeat

Nov 23, 2024